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Table 1
Outcomes
overall
All
patients
(N¼84)
(%)
Myeloid in CR
(N¼27) (%)
ALL
(N¼10)
(%)
Lymphoma/
CLL
(N¼14) (%)
P
NRM 25.7 8.9 33.3 25.0 0.17
Relapse Rate 32.0 24.3 25.0 21.4 0.96
PFS 42.3 66.8 41.7 53.6 0.22
aGVHD II-IV 32.6 26.9 50.0 35.7 0.46
aGVHD III-IV 7.8 0 37.5 7.1 0.0038
cGVHD
Lim.+Ext.
21.3 21.7 57.1 17.9 0.11
cGVHD Ext.
only
10.2 17.7 17.1 0 0.36
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140mg/m2 with ﬂudarabine, +/- thiotepa previously
described by us (Ciurea SO, BBMT 2012;18:1835). All had a
bone marrow graft except 4 pts (95%). Diagnoses were AML/
MDS 49 (58.3%), CML 9 (11%), ALL 10 (12%), and lymphoma/
CLL 13 (15%) (4 Hodgkin’s, 4 NHL, 5 CLL), other 3 (3.6%). 28/46
(61%) pts with myeloid diseases were in CR at transplant, and
15/21 pts with AML in remission had poor-risk cytogenetics.
Donors were siblings (N¼36), children (N¼35), parents
(N¼12), cousin (N¼1).
Results: All pts achieved engraftment except 3 (96.4%), 91.6%
with full donor chimerism. Median time to neutrophil
engraftment was 18 days (11-43 days). The cumulative inci-
dence of acute and cGVHD for different groups is presented
in Table 1. Overall, for the entire cohort, the NRM was 25.7%,
relapse rate was 32% and PFS was 42.3%. The median OS for
ﬁrst transplants was 25.6months (mo) and 6.5mo for second
transplant pts. For pts receiving their ﬁrst transplant, PFS was
similar for those who received full and RIC. Of the 49 pts who
had ﬁrst transplant for AML/MDS, 27 (55.1%) were in
complete remission prior to transplant. NRM for these pts
was 9%, relapse rate 24.3% and PFS 66.8% at 50 mo of median
follow-up (Table 1, Figure 1B).
Conclusions: Melphalan-based conditioning for HaploSCT
offers good disease control with low treatment-related
mortality. Factors associated with survival were protocol
eligibility and remission status for myeloid diseases while
the melphalan dose did not impact outcomes. A low relapse
rate was observed for lymphoma/CLL pts.
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and Donation-Related Pain and Slow Recovery: First
Report from the Related Donor Safety Study (RDSafe)
Michael A. Pulsipher 1, Pintip Chitphakdithai 2, Brent R. Logan 3,
Galen E. Switzer 4, Marcie R. Tomblyn 5, J. Douglas Rizzo 6,Figure 1. A. PFS ﬁrst transplants, all patients; BPaolo Anderlini 7, Susan F. Leitman 8, James W. Varni 9,
Amy Hays 2, Hati Kobusingye 10, John P. Miller 11,
Rebecca J. Drexler 2, Roberta King 12, Mary M. Horowitz 6,
Dennis L. Confer 13, Willis H. Navarro 2. 1Primary Children’s
Medical Center, University of Utah School of Medicine, Salt Lake
City, UT; 2CIBMTR, National Marrow Donor Program,
Minneapolis, MN; 3Division of Biostatistics, Medical College of
Wisconsin, Milwaukee, WI; 4University of Pittsburgh,
Pittsburgh, PA; 5H. Lee Mofﬁtt Cancer Center, Tampa, FL;
6CIBMTR, CIBMTR/Medical College of Wisconsin, Milwaukee,
WI; 7Stem Cell Transplantation and Cellular Therapy, The
University of Texas MD Anderson Cancer Center, Houston, TX;
8National Heart Lung and Blood Institute - NIH, Bethesda, MD;
9Texas A&M University, College Station, TX; 10CIBMTR,
Minneapolis, MN; 11National Marrow Donor Program,
Minneapolis, MN; 12CIBMTR, CIBMTR/Minneapolis Campus,
Minneapolis, MN; 13CIBMTR/National Marrow Donor Program,
Minneapolis, MN
As the use of hematopoietic cell transplantation (HCT) in
older patients has increased over the past decade, so too have
donations from their older siblings. Prospective data
addressing the experiences of older donors are limited,
though such donors are more likely than younger donors to
have comorbidities, and are often motivated to give in spite
of potential risks. To address this lack of data, the NHLBI-
funded Related Donor Safety Study (RDSafe) prospectively
enrolled related donors of all ages between 2010-2013 at 54
transplant centers in the United States, assessed their pre-
donation comorbidities and health status, and followed them
for 1 year after donation, collecting detailed information on
pain levels and 12 additional frequently noted symptoms,
e.g., nausea, vomiting, insomnia. This report describes early
experiences of 256 donors age >60.
Results: At baseline there were high rates of pre-G-CSF pain
and symptoms in older donors, with 28% experiencing
grades 1-3 pain and 17% grades 1-3 symptoms (baseline rates
from earlier NMDP data for 41-60 year olds were 9% and 5%,
respectively, with no grade 3 or greater). Peak rates of all
grades of pain and symptoms at day 5 of G-CSF (day 1 of
collection) were 69% and 49%, respectively (see ﬁgure). Of
note, 11% experienced grades 3-4 pain; in contrast, for 41-60
year old NMDP donors, 89% experienced any grade pain; 3%,
grade 3-4 pain. Assessment at 1 month showed that 68% and
78% of older donors had returned to baseline pain and other
symptom levels while 16% and 6% still reported grade 2-3
pain and symptoms, respectively (NMDP recovery: 96% at 1
month for both). Univariate analysis of the effect of gender,
race, age, and baseline rates of pain and symptoms on G-CSF-
related pain and symptoms, and return to baseline at one
month was performed. Donors with grade 2-3 pain at. PFS for myeloid patients in remission.
Figure 1. Pain and Symptoms Pre-, During, and Post-Collection in Older
Related Donors
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experience grade 2-4 pain (62 vs. 28%; p¼0.001) and grade 2-
4 symptoms (35 vs. 14%; p¼0.01) on day 5 of G-CSF. Female
donors showed lower rates of return to baseline symptom
levels at one month (72 vs. 85%, female vs. male; p¼0.028).
Race and ages 61-65, 66-70, and 71+ had no effect.
Conclusions: Related donors over age 60 have high baseline
rates of pain and other symptoms. Their rate of any grade
pain is lower but grade 3-4 pain is higher on the day of
collection and recovery at one month is slower than noted in
past studies of younger unrelated donors. Donors with
baseline pain are at risk of experiencing higher levels of pain
and symptoms during the collection process, and women
recovermore slowly thanmen. Additional analyses including
baseline organ-speciﬁc comorbidities and multivariable
analysis of risk will be presented with these data.
31
Who Is the Best Haematopoietic Stem Cell Donor for a
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Background: Female donors for male recipients worsens
outcome of allogeneic haematopoietic stem cell trans-
plantation (HSCT). We wanted to ﬁnd out whether a maleHLA-matched unrelated donor (MUD, 8/8, n¼2,014)might be
an alternative to a female HLA-identical sibling donor
(n¼2,656) for males with acute leukaemia.
Methods: A retrospective analysis from the Acute Leukemia
Working Party of the European Group for Blood and Marrow
Transplantation.
Results: The relative risk (RR) of acute GVHD of grades IIeIV
was increased in the MUD group with acute myeloid
leukaemia (AML) (RR 1.47, p<0.001) and acute lymphoblastic
leukaemia (ALL) (RR 1.76, p<0.001). There was no difference
in incidence of chronic GVHD and non-relapse mortality
between the two groups. Probability of relapse was lower in
the MUD group than in the sibling group in ALL patients (HR
0.75, p¼0.04) but not in AML patients (HR 0.89, p¼0.17).
Survival was not different between the groups. Leukaemia-
free survival (LFS) was also similar in the sibling and MUD
groups in patients with AML (HR 1.01, p¼0.81) or ALL (HR
0.93, p¼0.45). Factors signiﬁcantly associated with reduced
LFS included active disease, poor cytogenetics, age, year of
HSCT, reduced-intensity conditioning, and the use of anti-
thymocyte globulin.
Conclusion: Male patients who received grafts from male
MUDs had an increased incidence of acute GVHD and the
same LFS as when using HLA-identical female donors.32
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We have previously reported a lower than expected inci-
dence of acute GVHD in recipients of sibling donor allogeneic
HSC transplants mobilized with GM-CSF alone (Devine et al.
BMT 2005). However, the use of GM-CSF as a single agent for
stem cell mobilization has been limited by a high (w30%)
incidence of failure to mobilize and collect adequate stem
cell numbers in a single apheresis procedure. Based on
observed synergy between GM-CSF and plerixafor for HSC
mobilization in mice, we hypothesized that this combination
in humansmight overcome the low stem cell yields observed
with either agent alone and result in a PBSC product enriched
in Tregs and MDSCs that could reduce GvHD after transplant.
The efﬁcacy of GM-CSF (initially given 10 mcg/kg SC daily x 5
e 6 days but reduced to 5mcg/kg daily secondary to toxicity),
and plerixafor (320 mcg/kg IV daily starting on day 5) was
tested in a phase II trial.
The primary objective of this trial was reduction in the day 1
mobilization failure rate from 33% to <10%. We planned to
enroll 17 donor recipient pairs. Donors failing to reach 20L
apheresis volume were replaced. To date 22 donors (4 at
10mcg/kg GM-CSF and 18 at 5mcg/kg GM-CSF) have been
mobilized and 19 recipients transplanted. Initial mobilization
with GM-CSF 10mcg/kg was complicated by catheter and IV
tubing-associated thrombosis at the time of apheresis in 4/4
donors. Because of this, GM-CSF dose was reduced to 5 mcg/
kg SC daily x 5e6 days. Since this dose reduction, access
complications have occurred in 3/18 donors that precluded a
full 20 L apheresis. There has been no grade 3e4 adverse
events related to mobilization.
